Biosimilars Compounding Pharmacies Dosage 
Pharmacy Times
JUNE 27, 2025
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)
Pharmacy Times
JUNE 25, 2025
It will be interesting to see what dosage form these data prompt the future development of. It also introduces a question on how to optimize the PK/pharmacodynamic profile for protein degraders, such as cereblon E3 ligase modulatory drugs and proteolysis-targeting chimeras, which are a burgeoning area of therapeutic development.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JUNE 27, 2025
Misconceptions about biosimilars include doubts about their safety, efficacy, and risks associated with switching from reference biologics. Biosimilars extend beyond cost savings, improving access to essential treatments, especially in underserved populations. 2 Misconceptions About Biosimilars Biosimilars are the same as generics.
Pharmacy Times
JULY 4, 2025
The study's primary objective was to assess reversion rates to Humira, with 9% reverting after three months, while 91% remained on biosimilars or switched to alternatives. SHOW MORE Real-world data shows patients switching from Humira to biosimilars Hadlima and Hyrimoz achieve similar outcomes without hospitalization.
Pharmacy Times
JULY 12, 2025
Animal studies reveal dose-dependent hepatic responses to CBD, supporting the need for cautious monitoring even at consumer-relevant dosages. Pharmacists should review patient medication profiles, advise on appropriate dosage adjustments, and monitor for cumulative toxicity. of healthy adults, necessitating liver function monitoring.
Pharmacy Times
JUNE 17, 2025
Subscribe Now!
Pharmacy Times
JUNE 23, 2025
Additionally, ANDA submissions should extrapolate the RLD safety and effectiveness data for drugs with the same active ingredients, dosage forms, strengths, routes, and labeling. In the 505(j) ANDA approval pathway, on the other hand, submissions can be multisource generic drugs; however, this pathway requires bioequivalence to the RLD.
Expert insights. Personalized for you.
22 
Let's personalize your content